Scientists at the Terasaki Institute for Biomedical Innovation, in collaboration with the University of Maryland School of Pharmacy, have developed a new nanoparticle therapy that tackles obesity through two complementary mechanisms: converting energy-storing white fat into calorie-burning beige fat while simultaneously reducing obesity-related inflammation.

Their findings, published in the Journal of Controlled Release, are detailed in an article titled “Apigenin-loaded nanoparticles for obesity intervention through immunomodulation and adipocyte browning.” This innovative approach addresses key limitations of current obesity treatments by precisely targeting adipose tissue with apigenin-loaded nanoparticles—enhancing therapeutic effects while minimizing potential side effects.

The research team, led by Dr. Alireza Hassani Najafabadi and Dr. Ryan M. Pearson, engineered specialized PLGA nanoparticles to deliver the natural compound apigenin directly to fat tissue. This targeted delivery system ensures optimal therapeutic effects while minimizing potential side effects throughout the body.